Financials in USD. Standardized financial statements.
A compact view of how Checkpoint Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $41,000 | $103,000 | $192,000 | $268,000 | $1.07M | $1.71M | $3.51M | $1.73M | $2.57M | $590,000 |
| Revenue Growth? | -60.2% | -46.4% | -28.4% | -74.9% | -37.4% | -51.3% | +103.2% | -32.9% | +335.6% | 0.0% |
| Cost of Revenue? | $0 | $43.57M | $49.83M | $48.45M | $16.35M | $19.32M | $33.65M | $19.08M | $20.27M | $11.32M |
| Gross Profit? | $41,000 | -$43.46M | -$49.63M | -$48.19M | -$15.28M | -$17.62M | -$30.15M | -$17.36M | -$17.70M | -$10.73M |
| Gross Margin? | +100.0% | -42197.1% | -25850.5% | -17979.5% | -1429.7% | -1031.4% | -859.9% | -1006.1% | -688.6% | -1819.2% |
| Operating Expenses? | $56.22M | $52.25M | $58.52M | $56.99M | $24.27M | $26.56M | $40.25M | $24.50M | $24.73M | $13.81M |
| Operating Income? | -$56.17M | -$52.15M | -$58.33M | -$56.72M | -$23.20M | -$24.85M | -$36.74M | -$22.77M | -$22.16M | -$13.22M |
| EBITDA? | -$56.17M | -$52.15M | -$53.88M | -$56.49M | -$23.20M | -$24.68M | -$36.74M | -$22.68M | -$22.12M | -$13.22M |
| Income Before Tax | -$56.24M | -$51.85M | -$62.62M | -$56.67M | -$23.08M | -$24.71M | -$36.37M | -$22.68M | -$22.46M | -$13.89M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$56.24M | -$51.85M | -$62.62M | -$56.62M | -$23.08M | -$24.71M | -$36.37M | -$22.68M | -$22.46M | -$13.89M |
| EPS? | $-1.42 | $-2.77 | $-7.09 | $-7.45 | $-4.13 | $-6.96 | $-12.74 | $-10.03 | $-10.43 | $-5.69 |
| Diluted EPS? | $-1.42 | $-2.77 | $-7.09 | $-7.45 | $-4.13 | $-6.96 | $-12.74 | $-10.03 | $-10.43 | $-5.69 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality